Saamya Biotech (India) IPO Review
Saamya Biotech (India) IPO is yet to receive analyst coverage — analyst reports and verdicts will be updated here as and when they are published. Subscription ran from 25 Sep 2007 to 28 Sep 2007. The issue size is ₹15 crore, entirely a fresh issue. In the meantime, you can track the live GMP and subscription status for early market signals.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Detailed review
Download our Android App to check other reviews.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Saamya Biotech (India) IPO?
Analyst coverage for Saamya Biotech (India) IPO has not been published yet. Verdicts will be added here as analyst reports come in. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of N/A mean for Saamya Biotech (India) IPO?
Analyst scoring is not yet available for Saamya Biotech (India) IPO. The score will be updated once analyst reports start coming in.
What was the actual listing price of Saamya Biotech (India) IPO?
Saamya Biotech (India) IPO listed on October 19, 2007 at ₹17.5, against the issue price of ₹10 — a gain of +75% (₹7.5 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Saamya Biotech (India) IPO?
The minimum lot size is 500 shares. Subscription ran from 25 Sep 2007 to 28 Sep 2007.
Explore Saamya Biotech (India) IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
